Uffe Klausen

Herlev, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.

Journal: Frontiers in immunology
Published: December 06, 2022

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.

Journal: Frontiers in oncology
Published: August 19, 2022

An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.

An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.

Journal: Oncoimmunology
Published: September 25, 2021

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms.

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms.

Journal: Frontiers in oncology
Published: December 03, 2020

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.

Journal: Frontiers in immunology
Published: August 14, 2020

Therapeutic cancer vaccination for treatment of haematological cancers

Therapeutic cancer vaccination for treatment of haematological cancers

Journal: Ugeskrift for laeger
Published: October 16, 2019

Cancer immune therapy for the treatment of haematological malignancies

Cancer immune therapy for the treatment of haematological malignancies

Journal: Ugeskrift for laeger
Published: March 15, 2019

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.

Journal: Blood cancer journal
Published: October 23, 2018

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.

Journal: Frontiers in immunology
Published: June 29, 2018

Cancer immune therapy for lymphoid malignancies: recent advances.

Cancer immune therapy for lymphoid malignancies: recent advances.

Journal: Seminars in immunopathology
Published: June 12, 2018

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Journal: Oncoimmunology
Published: August 17, 2017
Showing 1-11 of 11

Last Updated: 09/26/2026